핵산 치료제 CDMO 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 : 유형별, 서비스별, 용도별, 지역별 세분화 및 경쟁 구도(2020-2030년)
Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Service, by Application, by region, and Competition, 2020-2030F
상품코드:1878947
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 핵산 치료제 CDMO 시장은 2024년에 115억 2,000만 달러로 평가되었고, 2030년까지 연평균 복합 성장률(CAGR) 8.29%로 성장하여 185억 8,000만 달러에 이를 것으로 예측됩니다.
핵산 치료제는 치료 목적으로 유전자 발현을 조절하기 위해 DNA, RNA 등의 유전 물질을 이용하는 독자적인 의약품 카테고리로, 안티센스 올리고뉴클레오티드, 소간섭 RNA, 메신저 RNA 등의 양식을 포함합니다. 이러한 치료제를 대상으로 하는 세계 위탁개발생산(CDMO) 시장은 주로 바이오의약품 R&D 투자 확대, 신규 핵산 의약품 후보물질 파이프라인 증가, 전문적 제조 역량에 대한 중요한 수요에 의해 주도되고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
115억 2,000만 달러
시장 규모 : 2030년
185억 8,000만 달러
CAGR : 2025-2030년
8.29%
성장 속도가 가장 빠른 부문
RNA 기반 치료법
최대 시장
북미
주요 시장 성장 촉진요인
주요 시장 과제
주요 시장 동향
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 핵산 치료제 CDMO 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
유형별(유전자 치료, RNA 기반 치료)
서비스별(프로세스 개발 및 최적화, 제조 서비스, 분석 및 품질관리 서비스, 기타)
용도별(종양학, 유전성 질환, 감염증, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 핵산 치료제 CDMO 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 핵산 치료제 CDMO 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 핵산 치료제 CDMO 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 핵산 치료제 CDMO 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트(UAE)
남아프리카공화국
제10장 남미의 핵산 치료제 CDMO 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병(M&A)
제품 출시
최근 동향
제13장 세계의 핵산 치료제 CDMO 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Catalent Inc.
Thermo Fisher Scientific Inc.
Lonza Group Ltd.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Charles River Laboratories International, Inc.
Eurofins Genomics
Sirion Biotech GmbH
Oxford Biomedica Plc.
Danaher Corp.
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
The Global Nucleic Acid Therapeutics CDMO Market, valued at USD 11.52 Billion in 2024, is projected to experience a CAGR of 8.29% to reach USD 18.58 Billion by 2030. Nucleic acid therapeutics represent a distinct class of pharmaceutical products utilizing genetic material, such as DNA or RNA, to modulate gene expression for therapeutic purposes, encompassing modalities like antisense oligonucleotides, small interfering RNAs, and messenger RNAs. The global Contract Development and Manufacturing Organization (CDMO) market for these therapeutics is primarily driven by expanding biopharmaceutical research and development investments, the increasing pipeline of novel nucleic acid drug candidates, and the critical need for specialized manufacturing capabilities.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 11.52 Billion
Market Size 2030
USD 18.58 Billion
CAGR 2025-2030
8.29%
Fastest Growing Segment
RNA-based Therapies
Largest Market
North America
Key Market Drivers
The expanding therapeutic pipeline for nucleic acid modalities significantly underpins the growth of the Contract Development and Manufacturing Organization market. The increasing number of novel drug candidates, including antisense oligonucleotides, messenger RNAs, and small interfering RNAs, necessitates specialized expertise and infrastructure for their development and large-scale production. These modalities offer targeted approaches for previously intractable diseases, creating a robust demand for outsourced services. For example, according to the article "Advancements in clinical RNA therapeutics: Present developments and prospective outlooks" published in PMC in April 2024, the exploration of antisense oligonucleotide-based therapies alone has progressed through 100 Phase I trials, with 25% of these advancing to Phase II or III trials, indicating a substantial volume of candidates requiring further development and manufacturing support. This progression through clinical stages directly translates into a requirement for advanced process development, analytical testing, and Good Manufacturing Practice compliant production.
Key Market Challenges
The inherent complexity and scalability issues associated with manufacturing advanced nucleic acid therapeutics, particularly in consistently achieving required quality and purity standards at commercial production volumes, represent a significant impedance to the growth of the global Contract Development and Manufacturing Organization (CDMO) market. These modalities often require specialized equipment, highly controlled environments, and intricate purification processes, leading to elevated operational costs and extended development timelines for CDMOs. Such manufacturing intricacies limit the capacity of CDMOs to efficiently process the increasing pipeline of novel drug candidates, creating bottlenecks within the supply chain.
Key Market Trends
Strategic Capacity Expansion Initiatives represent a significant trend as Contract Development and Manufacturing Organizations invest heavily to meet the escalating demand for nucleic acid therapeutics. This involves constructing new facilities, expanding existing operational footprints, and integrating advanced equipment to enhance overall manufacturing throughput and capabilities. Such proactive investments are crucial for ensuring the reliable and timely supply of critical drug substances and products, thereby supporting the clinical and commercial progression of novel therapies. For instance, according to a BioSpace report in January 2024, Lonza projected flat sales for the year but confirmed mid-term guidance and reported full-year 2023 sales of $7.75 billion, driven by strong performance in its Biologics and Small Molecules divisions, highlighting sustained investment in its manufacturing network. In October 2024, Lonza also completed the acquisition of a large-scale biologics facility in Vacaville, US, from Roche, further expanding its capabilities and dedicating CHF 1.4 billion of CapEx in 2024 towards its organic investment program for future growth across technologies.
Key Market Players
Catalent Inc.
Thermo Fisher Scientific Inc.
Lonza Group Ltd.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Charles River Laboratories International, Inc.
Eurofins Genomics
Sirion Biotech GmbH
Oxford Biomedica Plc.
Danaher Corp.
Report Scope:
In this report, the Global Nucleic Acid Therapeutics CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Nucleic Acid Therapeutics CDMO Market, By Type:
Gene Therapy
RNA-based Therapies
Nucleic Acid Therapeutics CDMO Market, By Service:
Process Development & Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
Nucleic Acid Therapeutics CDMO Market, By Application:
Oncology
Genetic Disorders
Infectious Diseases
Others
Nucleic Acid Therapeutics CDMO Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Nucleic Acid Therapeutics CDMO Market.
Available Customizations:
Global Nucleic Acid Therapeutics CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Nucleic Acid Therapeutics CDMO Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Gene Therapy, RNA-based Therapies)
5.2.2. By Service (Process Development & Optimization, Manufacturing Services, Analytical and Quality Control Services, Others)
5.2.3. By Application (Oncology, Genetic Disorders, Infectious Diseases, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Nucleic Acid Therapeutics CDMO Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Service
6.2.3. By Application
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Nucleic Acid Therapeutics CDMO Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Service
6.3.1.2.3. By Application
6.3.2. Canada Nucleic Acid Therapeutics CDMO Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Service
6.3.2.2.3. By Application
6.3.3. Mexico Nucleic Acid Therapeutics CDMO Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Service
6.3.3.2.3. By Application
7. Europe Nucleic Acid Therapeutics CDMO Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Service
7.2.3. By Application
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Nucleic Acid Therapeutics CDMO Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Service
7.3.1.2.3. By Application
7.3.2. France Nucleic Acid Therapeutics CDMO Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Service
7.3.2.2.3. By Application
7.3.3. United Kingdom Nucleic Acid Therapeutics CDMO Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Service
7.3.3.2.3. By Application
7.3.4. Italy Nucleic Acid Therapeutics CDMO Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Service
7.3.4.2.3. By Application
7.3.5. Spain Nucleic Acid Therapeutics CDMO Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Service
7.3.5.2.3. By Application
8. Asia Pacific Nucleic Acid Therapeutics CDMO Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Service
8.2.3. By Application
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Nucleic Acid Therapeutics CDMO Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Service
8.3.1.2.3. By Application
8.3.2. India Nucleic Acid Therapeutics CDMO Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Service
8.3.2.2.3. By Application
8.3.3. Japan Nucleic Acid Therapeutics CDMO Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Service
8.3.3.2.3. By Application
8.3.4. South Korea Nucleic Acid Therapeutics CDMO Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Service
8.3.4.2.3. By Application
8.3.5. Australia Nucleic Acid Therapeutics CDMO Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Service
8.3.5.2.3. By Application
9. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Service
9.2.3. By Application
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Nucleic Acid Therapeutics CDMO Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Service
9.3.1.2.3. By Application
9.3.2. UAE Nucleic Acid Therapeutics CDMO Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Service
9.3.2.2.3. By Application
9.3.3. South Africa Nucleic Acid Therapeutics CDMO Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Service
9.3.3.2.3. By Application
10. South America Nucleic Acid Therapeutics CDMO Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Service
10.2.3. By Application
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Nucleic Acid Therapeutics CDMO Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Service
10.3.1.2.3. By Application
10.3.2. Colombia Nucleic Acid Therapeutics CDMO Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Service
10.3.2.2.3. By Application
10.3.3. Argentina Nucleic Acid Therapeutics CDMO Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Service
10.3.3.2.3. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Nucleic Acid Therapeutics CDMO Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Catalent Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific Inc.
15.3. Lonza Group Ltd.
15.4. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
15.5. Charles River Laboratories International, Inc.
